Gastrointestinal Manifestation of COVID-19 in Hospitalized Patients

Sukharani, Naintara; Kumar, Jitesh; Makheja, Kainat; Bai, Pinky; Sharma, Sucheta; Subash, Komal; Kamawal, Yasir; Shahid, Simra; Rizwan, Amber

doi:10.7759/cureus.18024

Cited by 5 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 affects the respiratory system and many other organ systems, including the neurologic system, [ 9 ] the heart [ 10 ] and the gastrointestinal system. [ 11 ] Chronic obstructive pulmonary disease (COPD) ranks high as a cause of death worldwide, but there is no clear evidence if it increases COVID-19 susceptibility. Patients with COPD have impaired immune responses and frequent respiratory infections.…”

Section: Discussionmentioning

confidence: 99%

Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Koc,

Unalli Ozmen,

Deniz

2023

Medicine

View full text Add to dashboard Cite

Severe acute respiratory syndrome-coronavirus 2 and its variants are still a concern for the World. The effectiveness of the BioNTech and Sinovac vaccines against the B.1.617.2 variant, particularly in the intensive care unit, has been unclear. This study aimed to investigate the vaccine effectiveness of BioNTech and Sinovac vaccines in reducing severe disease, intubation, and mortality rates in B.1.617.2 infected patients followed in the intensive care unit. The data of 208 unvaccinated and 234 vaccinated B.1.617.2 variants were retrospectively reviewed. Severe disease status, complaints, the percent oxygen saturation in the blood at the first admission, and other clinical information during follow-up were recorded. With the BioNTech and Sinovac vaccines being the most common in the region, mortality rate, severe disease, and intubation were more frequent in the unvaccinated group. As for survival rates, 58.5 (137) of the vaccinated and 35.1 % (73) of the unvaccinated survived. In the vaccinated group, 64.3 % (27) of vaccinated with 3 Sinovac, 80 % (16) of 2 Sinovac and 1 BioNTech, and 71.7 % of 2 BioNTech survived. Vaccination with 2 doses of BioNTech and 3 doses of Sinovac reduces mortality. Furthermore, 2 doses of Sinovac and 1 dose of BioNTech are more protective.

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Koc,

Unalli Ozmen,

Deniz

2023

Medicine

View full text Add to dashboard Cite

show abstract

“…In the present study, patients infected with B.1.617.2 variant had suffered more frequently from tiredness, however, cough and fever were more common complaints among the B.1.1.7 infected group. As time passed, the scientific world started to recognize the COVID-19 disease better and learned that it does not only affect the respiratory tract but many other organ systems, including the neurologic system (Attia et al 2021, Williamson et al 2022, cardiovascular system (Guo et al 2020) and the gastrointestinal system (GIS) (Sukharani et al 2021). In the present study, GIS symptoms were more common in the B.1.617.2 infected group.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Clinical and Laboratory Differences between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7

Koç

2022

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

At the end of 2019, the world met with the COVID-19 disease, which will affect all humanity.Later in the course, the genetic variants of SARS-CoV-2 have emerged, bringing new questions and concerns. This study investigated differences between patients infected with the B.1.1.7 (UK variant) and the B.1.617.2 (Delta variant) regarding patient complaints, intensive care unit (ICU) admission and stay time, intubation, severe disease, mortality rates, and laboratory parameters. Hospitalized 205 B.1.1.7 and 207 B.1.617.2 infected patients were included in the study. Laboratory parameters, admission complaints, and the percent saturation of oxygen in the blood (SpO2) were recorded on the same day as the diagnosis and clinical findings during their follow-up. Cough and fever were more common complaints in the B.1.1.7 infected group, whereas tiredness, joint pain, and gastrointestinal complaints were more frequent in patients infected with B.1.617.2. The B.1.617.2 infected group had higher severe disease, acute coronary syndrome (ACS), mortality rates, neutrophil, troponin, and ferritin levels. In conclusion, patients infected with B.1.617.2 had a higher risk of intubation, ACS, and mortality rates. Cough and fever were more common in B.1.1.7 infected group, whereas tiredness was more frequent in B.1.617.2 infected group. Vaccination with at least one dose of Pfizer-BioNTech or CoronaVac is independently associated with a decreased mortality risk caused by two variants (OR: 0.4).

show abstract

“…The clinical presentations of various diarrhea‐causing pathogens mimic COVID‐19 and may cause clinical misdiagnosis. Therefore, it is recommended to test for COVID‐19 in patients that are presenting with gastrointestinal symptoms 72 . However, an inadequate testing capacity along with a surge in COVID‐19 cases daily will prove arduous in the correct diagnosis and treatment of patients, especially children, presenting with diarrhea 29,73 …”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is recommended to test for COVID-19 in patients that are presenting with gastrointestinal symptoms. 72 However, an inadequate testing capacity along with a surge in COVID-19 cases daily will prove arduous in the correct diagnosis and treatment of patients, especially children, presenting with diarrhea. 29,73 In the past few years however, the prevalence of diarrhea has changed very little across Pakistan and management of the disease has brought a significant amount of reduction in childhood mortality.…”

Section: Discussionmentioning

confidence: 99%

The rise of diarrheal illnesses in the children of Pakistan amidst COVID‐19: A narrative review

Rahmat

Zubair

Abdi

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background In Pakistan, 74 children out of 1000 lose their lives annually due to diarrheal illness. This commentary addresses the contributing factors aggravating this growing dilemma and the effect of a simultaneous rise in COVID‐19 cases in a healthcare system ready to collapse, along with providing recommendations to alleviate the problems causing this spike in diarrheal cases. Methods This narrative review has emphasized the causes of the spike in pediatric diarrheal illnesses in Pakistan as well as recommendations offered to lessen the burden by incorporating recent literature ( n = 68). Tactics to tackle COVID‐19 alongside diarrheal illnesses were also included. Pakistan was chosen to be assessed due to its high burden of child and infant mortality due to preventable causes. Results The provision of safe drinking water, the proper use of Integrated Management of Newborn and Childhood Illnesses (IMNCI), adequate awareness of the benefits of breastfeeding, the use of correct rehydration techniques such as Oral Rehydration Therapy, and the crucial implementation of the EPI vaccination schedule can curb this increase in diarrheal cases. Conclusion The increased prevalence of diarrheal diseases amongst the pediatric population of Pakistan can be attributed largely due to unsanitary drinking water. Emphasis must be put in the provision of safe drinking water. During the first years of life, children can be kept safe from deadly pathogens just by adequate breastfeeding. IMNCI and EPI must also be properly implemented.

show abstract

Gastrointestinal Manifestation of COVID-19 in Hospitalized Patients

Cited by 5 publications

References 16 publications

Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Clinical and Laboratory Differences between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7

The rise of diarrheal illnesses in the children of Pakistan amidst COVID‐19: A narrative review

Contact Info

Product

Resources

About